Bortezomib plus melphalan and prednisone for initial treatment of multiple myeloma.

@article{SanMiguel2008BortezomibPM,
  title={Bortezomib plus melphalan and prednisone for initial treatment of multiple myeloma.},
  author={Jes{\'u}s F. San Miguel and Rudolf Schlag and Nuriet K. Khuageva and Meletios- Athanasios Dimopoulos and Ofer Shpilberg and Martin H Kropff and Ivan {\vS}pi{\vc}ka and Maria Teresa Petrucci and Antonio Palumbo and Olga S Samoilova and Anna Dmoszyńska and Kudrat M Abdulkadyrov and Rik Schots and Bin Jiang and Maria Victoria Mateos and Kenneth C. Anderson and Dixie Lee Esseltine and Kevin Liu and Andrew Cakana and Helgi van de Velde and Paul G. Richardson},
  journal={The New England journal of medicine},
  year={2008},
  volume={359 9},
  pages={
          906-17
        }
}
BACKGROUND The standard treatment for patients with multiple myeloma who are not candidates for high-dose therapy is melphalan and prednisone. [...] Key MethodMETHODS We randomly assigned 682 patients to receive nine 6-week cycles of melphalan (at a dose of 9 mg per square meter of body-surface area) and prednisone (at a dose of 60 mg per square meter) on days 1 to 4, either alone or with bortezomib (at a dose of 1.3 mg per square meter) on days 1, 4, 8, 11, 22, 25, 29, and 32 during cycles 1 to 4 and on days 1…Expand
Bortezomib, low‐dose intravenous melphalan, and dexamethasone for patients with relapsed multiple myeloma
TLDR
Bortezomib and low‐dose IV melphalan combination therapy is a safe and highly effective regimen for patients with relapsed multiple myeloma and data suggest further investigation of this combination is warranted. Expand
Modified dose of melphalan-prednisone in multiple myeloma patients receiving bortezomib plus melphalan-prednisone treatment
TLDR
Modifying the dose of MP might be a feasible and effective therapeutic approach for multiple myeloma patients receiving VMP treatment, and more patients in the planned-dose group experienced earlier discontinuation in general. Expand
Bortezomib plus melphalan and prednisone for multiple myeloma.
TLDR
Lenalidomide and dexamethasone are the most effective treatment in patients with multiple myeloma who are not candidates for high-dose therapy, and unlike bortezomib, lenalidomides can be given orally and with minimal toxic side effects. Expand
Phase I/II study of bortezomib‐melphalan‐prednisolone for previously untreated Japanese patients with multiple myeloma
TLDR
Bortezomib‐melphalan‐prednisolone with 1.3‐mg/m2 bortzomib was considered to be tolerable and effective in Japanese patients with previously untreated multiple myeloma, however, further investigation is needed to refine the administration schedule. Expand
Sequential therapy of four cycles of bortezomib, melphalan, and prednisolone followed by continuous lenalidomide and dexamethasone for transplant-ineligible newly diagnosed multiple myeloma
TLDR
Se sequential therapy with VMP followed by Rd is effective and mostly feasible for transplant-ineligible NDMM. Expand
Intravenous injection of bortezomib, melphalan and dexamethasone in refractory and relapsed multiple myeloma.
TLDR
Observations suggest that BMD is an effective regimen in advanced myeloma patients with acceptable toxicity, and in a cohort of relapsed/refractory patients achieving at least partial remission improved PFS and OS. Expand
Bortezomib, melphalan, and prednisone in elderly relapsed/refractory multiple myeloma patients: update of multicenter, open-label Phase 1/2 study
TLDR
The ‘Velcade as Initial Standard Therapy in Multiple Myeloma: Assessment With Melphalan and Prednisone’ (VISTA) trial identified VMP as one of the new standards of care for patients with newly diagnosed multiple myeloma (MM) not eligible for transplantation with lower toxicity and comparable efficacy. Expand
Phase 1/2 study of carfilzomib plus melphalan and prednisone in patients aged over 65 years with newly diagnosed multiple myeloma.
TLDR
The combination of CMP was observed to be effective in elderly patients with newly diagnosed multiple myeloma and the projected 3-year overall survival rate was 80%. Expand
Bortezomib and thalidomide, a steroid free regimen in newly diagnosed patients with multiple myeloma
TLDR
This study demonstrates the efficacy of a steroid‐free regimen; the mostly reversible treatment‐related peripheral neuropathy; and the absence of venous thrombotic events in patients with symptomatic myeloma. Expand
Bortezomib and melphalan as a conditioning regimen for autologous stem cell transplantation in multiple myeloma
TLDR
Conditioning regimen consisting of bortezomib and melphalan may be effective for ASCT in MM; however, the feasibility of this regimen should be further evaluated in large study populations. Expand
...
1
2
3
4
5
...

References

SHOWING 1-10 OF 48 REFERENCES
Phase I/II trial assessing bortezomib and melphalan combination therapy for the treatment of patients with relapsed or refractory multiple myeloma.
TLDR
Bortezomib plus melphalan given on a 28-day schedule showed encouraging activity with manageable toxicity and represents a promising treatment for myeloma patients. Expand
Melphalan, prednisone, and lenalidomide treatment for newly diagnosed myeloma: a report from the GIMEMA--Italian Multiple Myeloma Network.
  • A. Palumbo, P. Falco, +15 authors M. Petrucci
  • Medicine
  • Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • 2007
TLDR
Oral MPR therapy is a promising first-line treatment for elderly myeloma patients and aspirin appears to provide adequate antithrombosis prophylaxis. Expand
A phase 2 study of two doses of bortezomib in relapsed or refractory myeloma
TLDR
Bortezomib alone or in combination with dexamethasone demonstrated therapeutic activity in patients with multiple myeloma who relapsed after frontline therapy. Expand
A phase 2 study of bortezomib in relapsed, refractory myeloma.
TLDR
Bortezomib, a member of a new class of anticancer drugs, is active in patients with relapsed multiple myeloma that is refractory to conventional chemotherapy. Expand
Bortezomib plus melphalan and prednisone in elderly untreated patients with multiple myeloma: results of a multicenter phase 1/2 study.
TLDR
In elderly patients ineligible for transplantation, the combination of bortezomib plus MP appears significantly superior to MP, producing very high CR rates, including immunophenotypic CRs, even in patients with poor prognostic features. Expand
Bortezomib plus melphalan and prednisone in elderly untreated patients with multiple myeloma: updated time-to-events results and prognostic factors for time to progression
TLDR
VMP is highly active and well tolerated in elderly patients with newly diagnosed muktiple myeloma, with 85% of patients alive at 3 years, and may overcome the poor prognostic impact of various factors, particularly cytogenetic abnormalities. Expand
Oral melphalan and prednisone chemotherapy plus thalidomide compared with melphalan and prednisone alone in elderly patients with multiple myeloma: randomised controlled trial
TLDR
Oral MPT is an effective first-line treatment for elderly patients with multiple myeloma and anticoagulant prophylaxis reduces frequency of thrombosis. Expand
Randomized comparison of dexamethasone combined with melphalan versus melphalan with prednisone in the treatment of elderly patients with multiple myeloma
TLDR
MP remains as the gold standard for treatment of MM and should be the reference for comparison of new therapeutic approaches involving novel agents, but non‐haematological toxicity was significantly higher in the MD arm. Expand
Treatment for multiple myeloma. Combination chemotherapy with different melphalan dose regimens.
TLDR
Results support the use of intermittent courses of concurrent chemotherapy with large doses of melphalan and prednisone in patients with multiple myeloma. Expand
Dexamethasone-based regimens versus melphalan-prednisone for elderly multiple myeloma patients ineligible for high-dose therapy.
TLDR
Overall, these results indicated that dexamethasone should not be routinely recommended as first-line treatment in elderly patients with MM, and the standard melphalan-prednisone remained the best treatment choice when efficacy and patient comfort were both considered. Expand
...
1
2
3
4
5
...